Drug intelligence / Profile preview

BeneCeed

Development stage: Preclinical
Lead developer: Colcare Laboratories
Modality: Small Molecules
Administration: Oral

Overview

**BeneCeed** is a proprietary 200 mg cannabidiol (CBD) tablet developed by Columbia Care, designed as a solid-dose oral formulation for improved delivery of CBD. It is a broad-spectrum botanical cannabinoid investigational medicinal product (IMP) aimed at pharmaceutical-quality standards, with potential applications in behavioral health and other unmet medical needs. The tablet is being prepared for import to the UK for use in randomized placebo-controlled clinical trials, potentially marking the first such US-originated botanical cannabinoid IMP approved for import there.[4][7][10]

Brand names: BeneCeed

Beyond the preview

Go deeper on BeneCeed.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BeneCeed.

Explore the full profile